Esperion announced NEXLIZETTM (bempedoic acid and ezetimibe) tablets, the first approved oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering combination medicine is now available in the U.S.

As the first non-statin LDL-C lowering fixed dose combination medicine ever approved by the FDA, NEXLIZET offers healthcare providers the opportunity to simultaneously use complementary medicines in a single oral tablet with no titration. NEXLIZET is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. The effect of NEXLIZET on cardiovascular morbidity and mortality has not been determined. NEXLIZET lowered LDL-C by a mean of 38 percent compared to placebo when added on to maximally tolerated statins. Results have been published in The European Journal of Preventive Cardiology.

“I am excited to have a newly approved statin add-on combination medicine. “NEXLIZET offers substantial LDL-lowering efficacy with a positive risk-benefit profile. It is a single pill with a single co-pay and is indicated for patients struggling to reach their cholesterol goals despite diet plus maximally-tolerated statin therapy,” said Eliot A. Brinton, MD, FAHA, FNLA, FACE, President of the Utah Lipid Center, past-President of the American Board of Clinical Lipidology and advisor to Esperion. “I anticipate that NEXLIZET will become a go-to option after statins because it provides double the LDL-C lowering efficacy of ezetimibe, without the need for titration. It also has favorable safety and excellent access at a low cost for patients.”

“More than ever, health care providers are seeking more options to help the millions of patients reach their cholesterol goals and address their long-term health needs,” said Mark Glickman, chief commercial officer of Esperion. “NEXLIZET is highly anticipated, so we are responding by accelerating its commercial availability. HCPs can easily prescribe NEXLIZET because it does not require any extra paperwork or injection training, potentially limiting the need for additional human contact during these unique times.”

NEXLIZET is the second commercially available product from Esperion.